ReviewActa pharmaceutica Sinica. B2026
Nanotechnology-driven STING regulation for on-demand therapy.
Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway modulation with nanotechnology offers a promising strategy for the development of more effective and less toxic therapies. This review summarizes the latest clinical progress of STING agonists and inhibitors, with a particular focus on the role of nanomaterials in regulating the cGAS-STING pathway across a range of diseases. In oncology, STING activation enhances anti-tumor immunity by stimulating immune cells, while nanocarriers improve the stability and targeting precision of STING agonists, facilitating synergistic effects with other immunotherapies. In inflammatory and autoimmune diseases, regulating STING activation helps alleviate the production of excessive pro-inflammatory cytokines, restore immune homeostasis, and prevent tissue damage. Nanomaterials, such as cell-derived membranes, further enhance targeted delivery and biocompatibility, addressing key limitations of existing treatment strategies. What distinguishes this review is an in-depth analysis of the current clinical progress of STING agonists and inhibitors, providing a comprehensive overview of both ongoing clinical trials and preclinical advancements. We also critically evaluate the specific challenges encountered in translating STING nanomaterials into clinical practice. These challenges present significant barriers to the widespread application of STING-based therapies, underscoring the need for further optimization to realize their full potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.